

EYETRONIC® - Restoring Vision

LSI Presentation

Dana Point, March 19, 2024



Glaucoma

Progressive Loss of Vision



#1 cause for irreversible blindness

80 million -> 100 million by 2040

2% prevalence age 40+

3% in Asia

Standard of Care


Focus on the Eye



Drops



Surgery



MIGS



Management of IOP - intraocular pressure

Treating elevated IOP is **necessary**

But **not sufficient**


Patients continue to **lose vision**

40% have **NTG** - Normal Tension Glaucoma

70% in Asia have NTG

New Paradigm

Focus on the Optic Nerve



Glaucoma is an optic nerve neuropathy

Oxidative stress **terminates metabolism**

Nerve cells become **inactive**


Nerves lose their function – **vision is lost**

Cell death - apoptosis

Optic Nerve Stimulation (ONS)

Re-engaging non-active cells with electrical current

EYETRONIC®



Stimulates from **eye** to **cortex**

Reactivates cellular metabolism

Phosphenes as **biomarker**

800 patients in **8,000** sessions

No SAE (Serious Adverse Event)

CE certified based on 3 RCTS

Mode-of-Action and Effects of ONS

Preclinical data after optic nerve injury

Mode-of-Action

Neurotrophic factors

↑ IGF-1, BDNF, CNTF, FGF-2; ↓ TNF- α

Immunomodulation

↑ IL-10; ↓ IL-6, COX-2, NF-kB


Glutamine synthetase ↑

Intracellular Ca²⁺ ↑


Caspase 3 ↑

Perfusion ↑

Neuroprotection




Functional Neurorestoration



3 Effects

Structural Neurorestoration





Results with EYETRONIC®



12-month clinical outcomes in IOP patients

Elevated IOP Eyes (n=101)


Halt in Visual Field loss



Improved Visual Field




Mean Defect (dB) Visual Field perimetries





Results with EYETRONIC®

12-month clinical outcomes in NTG patients



Mean Defect (dB) Visual Field perimetries



EYETRONIC® Business Model

Recurrent revenue from electronic codes in \$BN market




„Pay-per-Use“

Access code @ \$4,500 - \$6,000

Unlimited scaleable

Zero COGS, no logistics

System lease or sale



Patient self-pay

Private insurance contracts

Reimbursement

Competitive Overview

No direct commercial competition


SAVIR Therapy (SAVIR Center, Germany)



multiple indications, incl. glaucoma

offered at clinic of founder

Okuvision GmbH (Germany)



Retinitis Pigmentosa

commercial (CE)

Chiba University (Japan)



Retinitis Pigmentosa

clinical stage (ePICO trial)

€4,000 - €5,350

Fund Raising \$12m+ Round A


Investing in EYETRONIC® for US market access

Investment Case

Experience from **6 EU** countries
SaaS business model
Long term clinical data published
US IITs to start Q2/24
IP with **20** patents

Large unmet clinical need
Market Cap Glaukos \$4.3bn

Use of Proceeds



The EYETRONIC® Team and Advisors

The Right to Sight is our Mission



Karl Schweitzer
CEO
JD, MSc Informatics, MBA



Holger Klemm
CTO
MSc Electrical Eng, MBA



Michael Kring
CFO
MSc Finance



Christian Schultz
COO
MD, PhD



Marian Gransow
R&D, Operations
MSc, PhD



Josephine Rygus
Mktg, T&E, Customer Service
MSc Psychology



Andreas Heszer
Quality & Reg Affairs

Clinical Advisors

Prof. Carl Erb, MD, PhD
Head of Klinik am Wittenbergplatz Berlin

Prof. Jeffrey Goldberg, MD, PhD
Chair of Ophthalmology Byers Eye Institute
and Head of Glaucoma, Stanford University

Prof. Andrew Iwach, MD, PhD
Associate Clinical Professor of Ophthalmology UCSF
Executive Director of the Glaucoma Center of San Francisco
and the Glaucoma Education and Research Group

Dr. Ehsan Sadri, MD FACS
Founder and CEO Visionary Eye Institute Newport Beach

EYETRONIC® - Restoring Vision

Invest in neuromodulation and the future of ophthalmology!



USA

Eyetronic Inc
17331 Newhope Street
CA 92708-4343 Fountain Valley
United States of America

Europe

Neuromodtronic GmbH
Rosa-Luxemburg-Straße 3
D-03044 Cottbus
Germany

e-mail: therapy@eyetronic.com

EYETRONIC® - Bibliography

Sources

Prevalence of glaucoma

- Crabb, Eye (Lond) 30: 304-13, 2016
- Esporcatte and Tavares, Arq Bras Oftalmol 79: 270-6, 2016
- Weinreb et al., JAMA 311:1901-11, 2014
- Quigley & Broman, Br J Ophthalmol 2006; 90:262–267, 2006

Glaucoma

- Cordeiro et al., BRAIN 2017: 140; 1757-1767
- De Moraes et al., Prog Ret Eye Res 56:107-47, 2017
- Wojcik-Gryciuk et al., Restor Neurol Neurosci 34: 107-23, 2015
- Garway-Heath et al, Lancet 2015; 385:1295-304
- Porciatti & Ventura, J Neuroophthalmol 32: 354-8, 2012
- Stanfield, Principles of Human Physiology, 4th Edition, Pearson, 2011
- Jones, Netter's Neurology, Elsevier, 2005
- Cordeiro et al., PNAS, vol 101, no 36, September 2004

Preclinical evidence of optic nerve stimulation in glaucoma

- A.H.Jassim et al., Ann Biomed Eng 2020, Sep 24. doi 10.1007/s10439

Pre-clinical evidence and mode-of action of optic nerve stimulation

- Hanif et al., Exp Eye Res 149: 75-83, 2016
- Yin et al., Brain Res 1650: 10-20, 2016
- Fu et al., Graefes Arch Clin Exp Ophtalmol 253: 171-6, 2015
- Tagami et al., Jpn J Ophthalmol 53:257-66, 2009
- Miyake et al., Invest Ophthalmol Vis Sci 48:2356-61, 2007
- Morimoto et al., Invest ophthalmol Vis Sci 46: 2147-55, 2005

Clinical evidence of optic nerve stimulation

- Haberbosch et al., Front. Hum. Neurosci.13:43., 2019
- G Granata et al., Brain Stim 12 (2019), 800-802
- Erb, Ellrich, DOG, 2017
- Gall et al., PLOS ONE; 10.1371, 2016
- S Schmidt et al., Brian Stim 6 (2013), 87-93
- A Fedorov et al., Brain Stim 4 (2011), 189-201
- Colombo et al., Exp Eye Res (2021):108601

Neuromodulation – Ophthalmology

- J Katz, Expert Review of Ophthalmology, 2016, Vol.11, No 5, 325-327
- Fu-Graefes, Arch Clin Exp Ophthalmol (2015) 253:171-176